Chiesi, Atopix deal

Chiesi will acquire Atopix in a deal that could exceed €75 million ($80 million), including undisclosed milestones. Atopix’s OC459, a prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2; CRTH2; GPR44...